Method of Detection
High-throughput laboratory deployment
Generate relevant data on anything from impairing drug concentration to metabolic biomarkers affected by therapy with a simple workflow that takes advantage of widely available tools:
Point of Need/ Field-Use Testing
Generate actionable drug and biomarker data at the point of need — from impaired drug concentration to therapy-affected metabolic markers — through a simple, portable workflow:
CB1 Assay
A drop in solution to flag active THC (e.g., delta 8, delta 9, delta-10 & active metabolites like 11-OH-THC), semisynthetic cannabinoids (e.g., HHC, THC-O, THC-P), and fully synthetic (e.g., Spice, K-2, K-4) in a single screen.
Can additionally be used to determine the presence of the endogenous cannabinoids 2-AG and Anandamide when no exogenous agents are present in the sample.
KEY FEATURES:
- Sensors can discern active from inactive forms of THC, ensuring only those who are impaired at the time of the test are flagged as positive
- Quantitative measurements of active THC can be detected at the lowest levels mentioned in any international laws or regulations.
- Confirmed activity of our CB1 biosensor to detect active THC at a low cutoff has formed the basis for engagement with performing toxicology laboratories
- Registration enabling studies are ongoing in preparation of a LDT filing with the NYDOH
- CB1 sensors have clear applicability in metabolic panels, given the numerous re-emergent therapeutics targeting the receptor in diabetes and obesity
Our CB1 biosensor construct has demonstrated a dose response curve with sensitivity down to 5nM THC (~1.6ng/mL) through to 160nM THC (~50.9ng/mL)
GLP-1 Assay
An easy to deploy method to determine therapeutic concentrations of single agonists of GLP-1 (e.g., Semaglutide, Dulaglutide, and Liraglutide) as well as endogenous concentrations of active GLP-1 peptides (7-37 and 7-36 amide), while excluding the metabolized inactive forms (9-37, 9-36 amide).
- Internal Development has begun, data coming soon
- Exploratory biomarker discovery to follow
- In discussions with 3rd party laboratories and biopharma surrounding co-development
Mu Opioid Assay
A drop-in solution to flag any active compound within the opioid class including natural (e.g., morphine, codeine, and opium), semisynthetic (e.g., oxycodone, hydrocodone, and oxymorphone), and fully synthetic (e.g., fentanyl, methadone, tramadol) in a single screen. Can additionally detect the presence of endogenous opioid biomarkers.
- Confirmed activity of Mu Opioid biosensor to detect both exogenous (morphine) and endogenous opioids (endomorphin I & II)
- In discussions with 3rd party laboratories in order to validate, register, and launch the test in both toxicology and as a therapeutic drug management (TDM) tool
- Exploring the applicability of endogenous opioid biomarkers in chronic neuropathic pain and other chronic pain conditions
Multiplexed Panels
A solution for generating more in-depth physiological data on patient response to therapeutics, by taking advantage of multiple receptors in the same class. We have filed IP coverage for expanding our panel targets in a multiplexed assay. This will make it easier to identify relationships between levels of endogenous biomarkers and pharmacologic agents, enabling physicians to objectively identify metabolic status and optimize treatment selection / therapeutic window for the patient.
- We have developed a broad set of receptors within the opioid class as a proof of concept
- Additional development for cannabinoids and incretins to follow shortly after
- Exploratory biomarker work for broad opioid panels to identify neuropathy to begin soon
